FDA published PARPi results by biomarker. Largest to date — confirming prior data that ATM and CHEK2 have poor response. High number for BRCA, CDK12, PALB2 adds confidence for good ORR + PFS

ascopubs.org/doi/abs/10.120…

Happy to share our editorial recently published in Cancer Cell! - Chadi Hage Chehade
Neeraj Agarwal, MD, FASCO Umang Swami Benjamin L Maughan Georges Gebrael GU Cancer Research Program @HuntsmanCancer
oncodaily.com/59625.html

#Cancer #OncoDaily #Oncology #RCC #Cancer Biomarkers #Cancer Research

#AUA24 Amer. Urol. Assn. 👉 Most pts (63%) diagnosed with mCRPC (even in 2023) never received prior NHT. NHT remains most common Rx in 1L mCRPC (even in pts treated with prior NHT). Neeraj Agarwal, MD, FASCO Pedro C Barata, MD MSc FACP OncoAlert UroToday.com PCF Science GU Cancer Research Program @HuntsmanCancer

Just in JAMA Network Open 👉Our paper on treatment trends and attrition rates for advanced #bladdercancer in the US👉2/3rd of patients did not receive even 2nd-line Rx. Grateful for mentorship by Umang Swami Neeraj Agarwal, MD, FASCO. Link👉 bit.ly/3UHwBgv GU Cancer Research Program @HuntsmanCancer OncoAlert

🔥 📰 Hot of the press: sharing our work on HRR testing for prostate cancer using US database. Most mCRPC still don't get HRR testing. +pts being tested earlier. Race, age, insurance, low socioecon st, outside academia⏩ low testing Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO Rana McKay 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏

Just in Cancer Cell 👉Validation of the molecular clusters of the IMmotion151 trial in the JAVELIN Renal 101 dataset #kidneycancer : Excellent commentary highlighting these biomarkers by our fellow Chadi Hage Chehade 👇tinyurl.com/48px5rw8 GU Cancer Research Program @HuntsmanCancer OncoAlert UroToday.com KidneyCAN

Just in BMC 👉Full protocol of our recently initiated, National Cancer Institute RO1 funded, randomized trial of creatine supplementation + Resistance training in advanced #ProstateCancer undergoing ADT Adriana M Coletta, PhD, MS, RD Neli Ulrich, PhD OncoAlert PCF Science Huntsman Cancer Institute UroToday.com

Happy to share our work on transcriptomic profiles in RCC - 2 years later we can see the is come to live just in time to honor our senior author and Chris Wood rising star awardee Rana McKay!!
jci.org/articles/view/…

Amazing group Shuchi Gulati MD Tian Zhang, MD, MHS chadi nabhan MD, MBA, FACP

Just in ACS Journal Cancer 👉Pts w/ clear cell mRCC #kidneycancer from real world Flatiron database s/p ICI Rx👉 Similar survival w/ cabo + ICI vs. cabo monoRx aligning w/ #CONTACT03 trial results UroToday.com OncoAlert @huntsmangu Umang Swami Neeraj Agarwal, MD, FASCO 👇tinyurl.com/2w79fbt8

Just in 👉data from SWOG Cancer Research Network 1216 trial in mHSPC#prostatecancer👉 PSA level at 3 and 7 months after starting ADT Rx are strongly prognostic of OS: It’s time to design de- or escalation trials based on response biomarkers. OPEN access👉 tinyurl.com/3azhpt4r OncoAlert UroToday.com

🔥 HOT OFF THE PRESS: Happy to share the results of *two* Phase 2 studies of cabozantinib in #AdrenalCancer in The Lancet Oncology from MD Anderson Cancer Center

Scroll down for more details ⬇️ #GUSM #GUOncology

Just in Eur Urol Focus 👉🏻Pts w/ synchronous (Dx-Mx ≤ 3 mos) vs metachronous mRCC #kidneycancer treated w/ 1st line ICI Rx ➡️worse clinical outcomes 👇🏻
tinyurl.com/kheb6542 Georges Gebrael Luis A. Meza Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO GU Cancer Research Program @HuntsmanCancer Genitourinary Cancer Research Team @CityofHope UroToday.com OncoAlert

Correct—this is only in the context that the cancer has already been treated with PD-1/PD-L1 treatment before and become resistant (ie started growing again).

Georges Gebrael ACS Journal Cancer UroToday.com OncoAlert Umang Swami Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO Toni Choueiri, MD Petros Grivas Shilpa Gupta Tian Zhang, MD, MHS jc Yüksel Ürün Amanda Nizam, MD Benjamin L Maughan Huntsman Cancer Institute So if I'm understanding this correctly as a lay person, in terms of outcome there is no benefit to adding an PD-1 immunotherapy component to cabozantinib for mRCC patients? Is that correct?

Beautiful work! Excellent real world confirmation of our observations in #CONTACT03 , don’t you think Toni Choueiri, MD? Congrats to Georges Gebrael Benjamin L Maughan Neeraj Agarwal, MD, FASCO Umang Swami & the Huntsman Cancer Institute team!

Off the press! ➡️

Our real-world evidence of similar survival outcomes with cabozantinib/ICI vs cabozantinib monotherapy after ICI in patients with mRCC.

Flatiron Health GU Cancer Research Program @HuntsmanCancer Huntsman Cancer Institute Neeraj Agarwal, MD, FASCO Umang Swami

The #ROAR study showed that #rucaparib had an acceptable safety & efficacy profile as an ADT-sparing approach in pts w/ high-risk biochemically recurrent #nmHSPC w/ #BRCA 1/2 or other homologous recombination repair mutations. Neeraj Agarwal, MD, FASCO Benjamin L Maughan doi.org/10.1093/oncolo…

Video Recap 📹 of our first year COA - Chromophobe and Oncocytic Tumor Alliance! Over $34,700 raised, 3 Million reached, our board members attended 8 conferences (no funds from COA paid for these), gave 5 presentations to raise awareness and we ANNOUNCED our FIRST RESEARCH GRANT!! 🎉

What a year it’s been! Learn…

APPLICATIONS OPEN 🎉
$75k - Chromophobe RCC Focus Award

This grant represents not just our commitment COA - Chromophobe and Oncocytic Tumor Alliance to #chrcc but also to a collaborative approach in supporting our grantees and future research for #chromophobe #kidneycancer

Read more here👇

(1/4) A tweetorial on P1 trial of selective GR antagonist, ORIC-101 ORIC Pharmaceuticals, in men with mCRPC progress on enzalutamide. A study that didn’t meet efficacy endpoint but biomarker studies provide new insights into the role of GR in resistance to AR antag shorturl.at/oXZ28